These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12757341)

  • 1. Heparin-coated circuits (Duraflo II) with reduced versus full anticoagulation during coronary artery bypass surgery.
    Ovrum E; Tangen G; Oystese R; Ringdal MA; Istad R
    J Card Surg; 2003; 18(2):140-6. PubMed ID: 12757341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations.
    Ovrum E; Tangen G; Oystese R; Ringdal MA; Istad R
    J Thorac Cardiovasc Surg; 2001 Feb; 121(2):324-30. PubMed ID: 11174738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparinized cardiopulmonary bypass and full heparin dose marginally improve clinical performance.
    Ovrum E; Am Holen E; Tangen G; Ringdal MA
    Ann Thorac Surg; 1996 Oct; 62(4):1128-33. PubMed ID: 8823101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial.
    Muehrcke DD; McCarthy PM; Kottke-Marchant K; Harasaki H; Pierre-Yared J; Borsh JA; Ogella DA; Cosgrove DM
    J Thorac Cardiovasc Surg; 1996 Aug; 112(2):472-83. PubMed ID: 8751516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin-coated versus uncoated extracorporeal circuit in patients undergoing coronary artery bypass graft surgery.
    Oliver WC; Nuttall GA; Ereth MH; Santrach PJ; Buda DA; Schaff HV
    J Cardiothorac Vasc Anesth; 2003 Apr; 17(2):165-70. PubMed ID: 12698396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective randomized trial of Duraflo II heparin-coated circuits in cardiac reoperations.
    McCarthy PM; Yared JP; Foster RC; Ogella DA; Borsh JA; Cosgrove DM
    Ann Thorac Surg; 1999 May; 67(5):1268-73. PubMed ID: 10355394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete heparin-coated (CBAS) cardiopulmonary bypass and reduced systemic heparin dose; effects on coagulation and fibrinolysis.
    Ovrum E; Brosstad F; Am Holen E; Tangen G; Abdelnoor M; Oystese R
    Eur J Cardiothorac Surg; 1996; 10(6):449-55. PubMed ID: 8817142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits.
    Aldea GS; Soltow LO; Chandler WL; Triggs CM; Vocelka CR; Crockett GI; Shin YT; Curtis WE; Verrier ED
    J Thorac Cardiovasc Surg; 2002 Apr; 123(4):742-55. PubMed ID: 11986603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement and granulocyte activation in two different types of heparinized extracorporeal circuits.
    Ovrum E; Mollnes TE; Fosse E; Holen EA; Tangen G; Abdelnoor M; Ringdal MA; Oystese R; Venge P
    J Thorac Cardiovasc Surg; 1995 Dec; 110(6):1623-32. PubMed ID: 8523872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of Duraflo II heparin treated extracorporeal circulation circuits (2nd version). The European Working Group on heparin coated extracorporeal circulation circuits.
    Wildevuur CR; Jansen PG; Bezemer PD; Kuik DJ; Eijsman L; Bruins P; De Jong AP; Van Hardevelt FW; Biervliet JD; Hasenkam JM; Kure HH; Knudsen L; Bellaiche L; Ahlburg P; Loisance DY; Baufreton C; Le Besnerais P; Bajan G; Matta A; Van Dyck M; Renotte MT; Ponlot-Lois A; Baele P; McGovern EA; Ahlvin E
    Eur J Cardiothorac Surg; 1997 Apr; 11(4):616-23; discussion 624-5. PubMed ID: 9151026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin-coated circuits and reduced systemic anticoagulation applied to 2500 consecutive first-time coronary artery bypass grafting procedures.
    Øvrum E; Tangen G; Tølløfsrud S; Ringdal MA
    Ann Thorac Surg; 2003 Oct; 76(4):1144-8; discussion 1148. PubMed ID: 14530001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurological and general outcome in low-risk coronary artery bypass patients using heparin coated circuits.
    Svenmarker S; Sandström E; Karlsson T; Häggmark S; Jansson E; Appelblad M; Lindholm R; Aberg T
    Eur J Cardiothorac Surg; 2001 Jan; 19(1):47-53. PubMed ID: 11163560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced systemic heparin dose with phosphorylcholine coated closed circuit in coronary operations.
    Ranucci M; Isgrò G; Soro G; Canziani A; Menicanti L; Frigiola A
    Int J Artif Organs; 2004 Apr; 27(4):311-9. PubMed ID: 15163065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin-coated cardiopulmonary bypass circuits in coronary bypass surgery.
    Horimoto H; Kondo K; Asada K; Sasaki S
    Artif Organs; 1996 Aug; 20(8):936-40. PubMed ID: 8853810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of polymethoxyethylacrylate-coated circuits with leukocyte filtration and reduced heparinization protocol on heparin-bonded circuits in different risk cohorts.
    Gunaydin S; McCusker K; Vijay V; Isbir S; Sari T; Onur MA; Gurpinar A; Sezgin A; Sargon MF; Tezcaner T; Zorlutuna Y
    Perfusion; 2006 Nov; 21(6):329-42. PubMed ID: 17312857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use of heparin-coated cardiopulmonary bypass in coronary artery bypass grafting.
    Mirow N; Minami K; Kleikamp G; Tenderich G; Puhlmann T; Körfer R
    Thorac Cardiovasc Surg; 2001 Jun; 49(3):131-6. PubMed ID: 11432470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative course and recovery after heparin-coated cardiopulmonary bypass: low-dose versus high-dose heparin management.
    Weiss BM; von Segesser LK; Turina MI; Seifert B; Pasch T
    J Cardiothorac Vasc Anesth; 1996 Jun; 10(4):464-70. PubMed ID: 8776638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes : a European multicentre study.
    Fosse E; Thelin S; Svennevig JL; Jansen P; Mollnes TE; Hack E; Venge P; Moen O; Brockmeier V; Dregelid E; Haldén E; Hagman L; Videm V; Pedersen T; Mohr B
    Eur J Cardiothorac Surg; 1997 Feb; 11(2):320-7. PubMed ID: 9080162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary artery bypass surgery with heparin-coated perfusion circuits and low-dose heparinization.
    Mullen JC; Bentley MJ; Gelfand ET; Koshal A; Modry DL; Guenther CR; Etches WS; Stang LJ; Lopushinsky SR
    Can J Surg; 2002 Jun; 45(3):166-72. PubMed ID: 12067167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Duraflo II heparin-coated cardiopulmonary bypass circuits on the coagulation system, endothelial damage, and cytokine release in patients with cardiac operation employing aprotinin and steroids.
    Inui K; Shimazaki Y; Watanabe T; Takahashi T; Minowa T; Takeda H; Yanagawa N; Sotoda Y
    Artif Organs; 1999 Dec; 23(12):1107-12. PubMed ID: 10619929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.